Share this video  

ASTRO 2022 | SALV-ENZA: SRT + enzalutamide in high-risk PSA-recurrent prostate cancer after radical prostatectomy

Phuoc Tran, MD, PhD, University of Maryland, MD, provides an overview of the rationale and study design of the SALV-ENZA (NCT02203695) trial, a Phase II double-blind, randomized study of salvage radiation therapy (SRT) plus enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy. The primary endpoint was freedom from PSA progression. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Employer: University of Maryland
Consulting: Bayer, RefleXion Medical Inc & J&J
IP: Natsar Pharm
Funding sources: Astellas Pharm, Bayer Healthcare, & RefleXion Medical Inc, NIH (U01CA212007, U01CA231776 & U54CA273956), DoD (W81XWH-21-1-0296), Anonymous Donor, PCF, Distinguished Gentlemen’s Ride, Movember, Nesbitt-McMaster Foundation, Barabara’s Fund, National Capitol Cancer Research Fund

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter